The immunohistochemical results of non-CNS lesions (determination of PD-1/PD-L1 expression) correlated well with the median SUVpeak for [18F]F-BMS986192 and [89Zr]Zr-Df-nivolumab: a higher SUVpeak for lesions with ≥50% tumor PD-L1 expression compared to lesions with <50% tumor PD-L1 expression for [18F]F-BMS986192 (8.2 vs. 2.9), and a higher SUVpeak for tumors with aggregates of PD-1 for [89Zr]Zr-Df-nivolumab (7.0 vs. 2.7). Here, CD274 is linked to neoplasm.